Aeterna Zentaris Inc. (Nasdaq: AEZS) Shares Up on Expectations of 2017 Developments

Aeterna Zentaris Inc. – Nasdaq: AEZS

Aeterna Zentaris shares traded up over 20% today on the belief that the company will be completed with Phase 3 testing and begin commercialization of two products in 2017. AEZS, traded on the Nasdaq, experienced volumes ten times normal in today’s trading session and the shares settled at $3.15.

Canadian-based Aeterna Zentaris has two drugs far along in its pipeline. The first is Macrilen, a drug designed to evaluate adults for growth hormone deficiency, is expected to deliver top-line results once the final stages of pivotal clinical testing are completed in early-2017. The other drug in development is Zoptrex, a treatment for advanced endometrial cancer, which has been re-engineered from an established chemotherapeutic agent. The new treatment is rumored to be safer in terms of side-effects, and reportedly provides extended chances for survival for women with advanced endometrial cancer.

AEZS shares have experienced negative EPS for the last five years but year-on-year EPS losses have been narrowing. In 2011 AEZS lost $168.75 per share. That loss narrowed to $18.18 in 2015. AEZS sales have been inconsistent and in 2015 Aeterna Zenatris posted just $500k. Two firms follow Aeterna Zentaris and both rate AEZS shares as a “Strong Buy” with a price target of $8.75.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/31/2017
Ticker Symbol AEZS
Last Price a/o 6:09 PM EST  $                      3.20
Average Volume                    279,030
Market Cap (mlns)  $                    37.55
Sales (mlns) $0.70
Shares Outstanding (mlns) 11.92
Share Float (mlns) 11.61
Shortable Yes
Optionable Yes
Inside Ownership 0.60%
Short Float 6.55%
Short Interest Ratio 2.73
Quarterly Return -17.54%
YTD Return -12.50%
Year Return 0.64%